Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 05/21 05:11:14 pm
18.3 EUR   +1.11%
04/24PCAS : Chiffre d'affaires au 31 Mars 2018
PU
04/24PCAS : Net sales as of march 31, 2018
GL
04/24PCAS : 1st quarter earnings
CO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

PCAS : 2011 RESULTS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2012 | 05:40pm CEST

PCAS - 2011 RESULTS

Longjumeau, february 22, 2012

20102011
In millions of euros
Net sales158,5  164,5  
including Pharmaceutical Synthesis99,4  102,1  
Including Fine Speciality Chemicals59,1  62,4  
EBITDA (*)16,1  16,5  
EBITDA margin10,2%10,0%
Current Operating Income (*)3,4  5,4  
Other Operating income and expense-2,2  -1,7  
Financial Result-4,2  -3,6  
Taxes (**)-0,9  -3,1  
Share of profit/loss of associates-0,1  0,2  
Net Result-4,0  -2,8  
Net Result (exluding depreciation of deferred tax asset)-4,0  0,2  
Equity71,6  69,2  
Net debt47,5  53,6  
Gearing0,66  0,77  
Net asset per share5,2  5,1  
(*) of which research tax credit (CIR): 2.8 million euros in 2011 and 2.7 in 2010
(**) including a depreciation of deferred tax asset for an amount of 3 M€ in 2011
Audit procedures have been performed and auditor's report is in progress of being issued.

PCAS Group consolidated turnover was up 3.8% in 2011 compared with 2010.

Pharmaceutical Synthesis
Business was affected during the first five months of the year by the lower planned contribution from the new contract between PCAS and Sanofi, in force as of May 31, 2010. apart from this contract, Exclusive and Generics  Pharma business rose 13.1% in 2011.
Fine Speciality Chemicals
Fine Speciality Chemicals reported growth of 5.6% in 2011.

Current Operating Income rose 60% to 5.4 million euros in 2011, compared with 3.4 million euros in 2010.

Net profit in 2011 was affected by a non recurring depreciation of deferred tax assets of 3 million euros (without any effect on cash), due to the effects of the French Goverment amending tax law for 2011 relating to the conditions for future use of loss carry forwards.

Excluding this non recurring item, net profit for 2011 stood at 0.2 million euros compared with (-4) million euros in 2010.

Net debt was 53.6 million euros as of December 31, 2011, compared with 47.5 million euros as of December 31, 2010, resulting from the increase in the working capital , due in particular to strong growth in turnover in the fourth quarter of 2011, as well as research tax credits, which are only refundable after a 3 years period.

To successfully implement the Group's development strategy, which is based on increasing the share of proprietary products and expanding differentiating technologies, the Board of Directors has asked the Group General Management to focus its action in 2012 on improving profitability and level of working capital.

Next meeting: 2012 Shareholder's Meeting at 9 .a.m. on April 24, 2012, in Longjumeau

About PCAS
PCAS is a fine and speciality chemicals Group that shares an ambition of excellence with its clients.  This client base comprises mainly international groups which are leaders in their markets.  PCAS designs and delivers the best industrial solutions to the specific expectations of its clients.  These wide-ranging expectations share in common a demand for safety, quality, competitiveness, innovation and sustainability.

PCAS_2011earning:
http://hugin.info/143512/R/1588264/498366.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

HUG#1588264
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
04/24PCAS : Chiffre d'affaires au 31 Mars 2018
PU
04/24PCAS : Net sales as of march 31, 2018
GL
04/24PCAS : 1st quarter earnings
CO
02/20PCAS : 2017 Annual Results
GL
02/15PCAS SA : annual earnings release
01/31PCAS : Net sales as of December 31, 2017
PU
01/31PCAS : Net sales as of december 31, 2017
GL
01/31PCAS : Net sales as of december 31, 2017
AQ
2017PCAS : Chiffre d'affaires au 30 septembre 2017
PU
2017PCAS : Résultats au 1er semestre 2017
PU
More news
Financials (€)
Sales 2018 227 M
EBIT 2018 20,6 M
Net income 2018 10,2 M
Debt 2018 47,9 M
Yield 2018 -
P/E ratio 2018 25,24
P/E ratio 2019 22,45
EV / Sales 2018 1,42x
EV / Sales 2019 1,34x
Capitalization 274 M
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 18,8 €
Spread / Average Target 2,5%
EPS Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Pierre Luzeau Chairman
Pierre Schreiner Chief Operating Officer
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Scientific Director
Sector and Competitors
1st jan.Capitalization (M$)
PCAS0.99%323
JOHNSON & JOHNSON-11.45%333 230
PFIZER-1.16%208 479
NOVARTIS-6.55%202 002
ROCHE HOLDING LTD.-8.90%195 055
MERCK AND COMPANY5.10%159 105